Codexis, Inc.

CDXS

$234M

Micro Cap

NASDAQIndustrial Organic ChemicalsProtein engineering🇺🇸North AmericaREDWOOD CITY165 employees

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 11, 2026

Market Overview

Stock performance and key metrics

CDXS News

Catalyst Timeline

1 upcoming, 0 past

EarningsNext

CDXS Earnings Report

Aug 11, 2026Confirmed

EPS Est: $-0.17 | FQ end 2026-06 | Call: 2026-08-11 15:00:00

How CDXS's past catalysts played out

earningsNov 2025-5%earningsAug 2025+7%earningsFeb 2025-6%earningsMay 2024+7%earningsFeb 2024-10%earningsNov 2023+7%earningsAug 2023+5%earningsNov 2022+11%

Drug Pipeline

No drugs found in this phase.

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

When is Codexis, Inc.'s next FDA catalyst?→

Codexis, Inc.'s (CDXS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track CDXS biotech catalysts?→

Add CDXS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Codexis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply